Sihuan Pharmaceutical Pediatric Medicine `Midazolam Oromucosal Solution` to be Listed in the Priority Review Pro
(WorldNews China)

2018-08-16 15:55:06 Copyfrom: Sihuan Pharmaceutical Holdings Group Ltd. HONG KONG, 16 August 2018 - Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) (`Sihuan Pharmaceutical` or the `Group`), the largest cardio-cerebral vascular (`CCV`) drug manufacturer in China`s prescription drug market, announced that its self-developed Category 3 generic drug Midazolam Oromucosal Solution (`Midazolam` or `the product`) was granted priority review designation as a pediatric medicine by the Center for Drug Evaluation of China Food and Drug Administration (`CFDA`). The inclusion in the priority review process is expected to expedite the review and approval timeframe for the drug to market. Currently...